lexicon-genetics.

technolgy redirect

It is anticipated that Mr. Johnson , Strategic E-mail: jdjohnson@strategic-ir. Lexicon is working both independently and through strategic
alliances to accelerate the development and commercialization of its
discoveries.

inventions deploys

Competitive Technologies, established in 1968, is a full service
technology transfer and licensing provider focused on the technology needs of
its customers and transforming those requirements into commercially viable
solutions.competitivetech.

technolgy transfer

, Europe and Asia. Zambrowicz' presentation may be accessed on
Lexicon's corporate website at http://www. Using its proprietary gene
knockout technology , Lexicon is systematically discovering the physiological
and behavioral functions of genes to identify potential points of therapeutic
intervention, or drug targets.

supercomputing technolgy

Dr.com .

incubator unitectra

Dr.

commercialization incubator

FAIRFIELD, Conn . Zambrowicz will also discuss Lexicon's new biotherapeutics
collaboration with Organon.lexicon-genetics .

commercialization startups

"

About Competitive Technologies, Inc.D.

collaborations commercialisation

Lexicon Genetics to Present at Needham + Company 's Fourth Annual Biotechnology Conference

contractual itek

,
Lexicon's executive vice president of research, will present at the Fourth
Annual Needham Biotechnology Conference at The New York Palace Hotel on
Wednesday , May 25, 2005 at 11:30 a.

biosciences commercialization

Nano will continue to be employed by the
Company on a consultancy basis . Dr. An archived
version of the webcast will be available on the website through June 2, 2005.

venturecatalyst transfer

Competitive Technologies Appoints Dr. Donald J. Freed as President and Chief Executive Officer Replacing John B . Nano

Visit CTT's website: http://www.

redirect contractual

This will provide for continuity by making his
expertise available to the Company in the future. (212) 754-6565; Fax: 212-754-4333 E-mail: ctt@competitivetech .

About Lexicon Genetics
Lexicon Genetics is a biopharmaceutical company focused on discovering and
developing new ways to treat human disease. Information identifying such important factors is contained under
"Factors Affecting Forward-Looking Statements" and "Business - Risk Factors "
in Lexicon's annual report on Form 10-K for the year ended December 31, 2004,
as filed with the Securities and Exchange Commission.

pathway commercialisation

, Competitive Technologies, Inc. Donald J. Freed an outstanding choice to lead our Company. When used herein, the words "anticipate," "believe," "intend,"
"plan ," "expect," "estimate," "approximate," and similar expressions, as they
relate to us or our business or management, are intended to identify such
forward-looking statements. These statements involve risks and uncertainties
related to market acceptance of and competition for our licensed technologies ,
growth strategies, operating performance, industry trends, and other risks
inherent in our business , including those set forth in Item 7 under the
caption "Risk Factors," in our most recent Annual Report on Form 10-K filed
with the SEC on October 29, 2004, and other factors that may be described in
our other filings with the SEC, and are subject to change at any time. Lexicon has advanced knockout -validated
targets into small molecule and biotherapeutic drug discovery programs in six
therapeutic areas: diabetes and obesity, cardiovascular disease, psychiatric
and neurological disorders, cancer , immune system disorders and ophthalmic
disease.

redirect startups

Nano, who has ceased to serve in those
positions . Richard E. Freed can provide the leadership to
achieve that goal.

Johnnie D. Lexicon undertakes no
obligation to update or revise any such forward-looking statements, whether as
a result of new information, future events or otherwise.

commercialization contractual

CTT is a global leader in identifying, developing and
commercializing innovative technologies in life, electronic, nano, and
physical sciences developed by universities, companies and inventors. Eastern Time.

redirect inventions

Freed, the Company's
Executive Vice President and Chief Technology Officer, has been appointed by
the Board of Directors to serve as President and Chief Executive Officer on an
interim basis, replacing Mr. Freed knows technology and how to manage technology
companies, and is particularly well-suited for continuing to develop CTT's
technology commercialization business.

unitectra weill

John B. Zambrowicz, Ph.

unitectra emanating

S.
We undertake no obligation to update publicly any forward-looking statement.

contractual biosciences

(Amex: CTT) announced that effective today Dr.
A live webcast of Dr.

deploys pathway

Our
actual results could differ materially from these forward-looking statements .

This category contains links to technology transfer offices that are associated with institutions such as universities, government laboratories, research hospitals, and more.

collaborations redirect

Carver, Chairman of the Board , said, "The Board of
Directors feels strongly about expanding our strategic vision for increased
recurring revenues, and I believe that Dr. Before joining us in 2004, Dr.net

THE WOODLANDS , Texas, Lexicon Genetics
Incorporated (Nasdaq: LEXG) announced today that Brian P.com .

Lexicon Genetics Safe Harbor Statement
This press release contains "forward-looking statements ," including
statements about Lexicon's growth and future operating results, discovery and
development of products, strategic alliances and intellectual property, as
well as other matters that are not historical facts or information.

inventions pathway

Freed
was responsible for the successful start-up of advanced materials initiatives
in three Fortune 50 companies, and has extensive experience in licensing and
technology transfer on a global basis, including the U.net

Statements about our future expectations , including development and
regulatory plans, and all other statements in this press release other than
historical facts are "forward-looking statements" within the meaning of
applicable Federal Securities Laws, and are not guarantees of future
performance.m. Additional information about Lexicon is available through its
corporate website, http://www.

pathway incubation

Mr. Zambrowicz will
provide an overview of Lexicon and discuss its drug discovery and development
programs. These
forward-looking statements are based on management's current assumptions and
expectations and involve risks, uncertainties and other important factors,
specifically including those relating to Lexicon's ability to successfully
conduct preclinical development of its drug candidates and advance such
candidates into clinical development, achieve its operational objectives,
obtain patent protection for its discoveries and establish strategic
alliances, as well as those relating to manufacturing, the regulatory process ,
intellectual property rights, and the therapeutic or commercial value of its
drug candidates , that may cause Lexicon's actual results to be materially
different from any future results expressed or implied by such forward-looking
statements.

incubation contractual

His knowledge of the Company, coupled with his excellent track record of
success, makes Dr. CTT
maximizes the value of intellectual assets for the benefit of its customers,
clients and shareholders.com
Tel.